Epidemiological, Clinical and Therapeutic Aspects of Chronic Lymphoid Hemopathies Observed at the National Reference University Hospital Center of N'Djamena

International Journal of Medical Science

© 2022 by SSRG - IJMS Journal

Volume 9 Issue 1

Year of Publication : 2022

Authors : Mbanga Djimadoum, Bessimbaye Nadlaou, Lopiagoto Kemteud Blaise

10.14445/23939117/IJMS-V9I1P101

How to Cite?

Mbanga Djimadoum, Bessimbaye Nadlaou, Lopiagoto Kemteud Blaise, "Epidemiological, Clinical and Therapeutic Aspects of Chronic Lymphoid Hemopathies Observed at the National Reference University Hospital Center of N'Djamena," SSRG International Journal of Medical Science, vol. 9,  no. 1, pp. 1-8, 2022. Crossref, https://doi.org/10.14445/23939117/IJMS-V9I1P101

Abstract:

Chronic lymphoid hemopathies (CHL) remain a major public health problem in low-income countries. It is therefore important to determine the epidemiological and clinical characteristics and to contribute to the care.
This study aims to determine the epidemiological and clinical profile and to contribute to better management of HLC in Chad.
The aim was to determine the epidemiological, clinical, therapeutic profile of chronic lymphoid hemopathies (CLH) and the viral factors linked to the genesis of HLCs at the CHU-RN of Ndjamena in Chad.
A descriptive cross-sectional study over two and a half years, from October 2017 to March 2020, at the Hematology Unit of the National Reference University Hospital Center (CHU-RN) of Ndjamena. Were included patients in whom the diagnosis of chronic lymphoid hemopathy had been made.
Ninety-eight (98) cases of haematological malignancies were recorded out of 531 haematological consultations, including 66 (12.43%) CLH and 67.35% of haematological malignancies with an annual incidence of 26.4 cases. Chronic lymphocytic leukemia (CLL) was 56.06% (n=37) followed by 25.76% (n=17) Malignant non-Hodgkin's lymphoma, 15.15% (n=10) Hodgkin's lymphoma and 3.03 % (n=2) cutaneous lymphoma. A male predominance was observed for all types of CLH. The most represented age groups were those of 51 to 60 years for CLL and 11 to 20 years for lymphomas.
This study made it possible to have a piece of better epidemiological knowledge and the viral factors related to the genesis of CLH at the CHU-RN of Ndjamena. It revealed difficulties in biological diagnosis and management, in particular the initiation of chemotherapy.

Keywords:

Chronic lymphoid hemopathies, Viral factors, CHU-RN, Ndjamena, Chad.

References:

[1] Swerdlow S.H, Campo E, Pileri S.A, Harris N.L, Stein H, Siebert R, Advani R, Ghielmini M, Salles G.A, Zelenetz A.D, Jaffe E.S, The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127 (20) (2016) 2375-2390. doi : 10.1182/blood-2016-01-643569
[2] Choquet S. Syndromes lymphoprolifératifs chronique chez la personne âgée: du diagnostic à la prise en charge. Bulletin cancer, (95) (2008) 74-78.
[3] Shaffer A.L, Rosenwald A, Staudt L.M. Lymphoid malignancies: The dark side of B-cell differentiation. Immunology. 2(12) (2002) 920-32.doi: 10.1038/nri953
[4] Smith A, Howell D, Patmore R, Jack A, Roman E, Incidence of haematological malignancy by sub-type: a report from the Hematological Malignancy Research Network. British Journal of Cancer. 105 (11) (2011) 1684-92. doi : 10.1038/bjc.2011.450.
[5] Jemal A, Siegel R, Xu J, Ward E., Cancer statistics. CA Cancer Journal Clinical. 60 (5) (2010) 277-300. doi : 10.3322/caac.20073
[6] Ngolet L, Okouango N.O, Elira D, Les hémopathies lymphoïdes chroniques à Brazzaville. Annales Université Marien Ngouabi, 17 (1) (2017) 33-38.
[7] Moueleu Ngalagou PT, Ngouadjeu Dongho Tsakeu E, Ngo Sack F, Eboumbou Moukoko EC, Konn Jolly Y, Luma H., Epidemiology of malignant hemopathies identified in hospitals in Cameroon. Tropical Medicine and Health, 28(1)(2018) 61-66. doi:10.1684/mst.2018.0759
[8] Koulidiati J, Ouedraogo DD, Tieno H, Bationo B, Kafando E, Drabo YJ., Hematological malignancies in adults in Ouagadougou (Burkina Faso): epidemiological, diagnostic and therapeutic aspects. Review CAMES SANTE, 3(2) (2015)10-16.
[9] International Agency for Research on Cancer., CANCER Mondial International Agency for Research on Cancer. Lyons, (2008).
[10] National Institute of Health and Medical Research (INSERM). Hematological malignancies: Risk factor in adults. Cancer and the Environment, (2009) 265-288.
[11] Ayemou R, Kouakou B, Méité N, Danho NC, Tolo A, Ndatz E, Kouehion P, Konan M, Kouassi Y, Kamara, Seka E, Silué DA, Koffi KG, Sanogo I. Contribution of immune phenotyping in the diagnosis of chronic lymphoproliferative syndromes (CLPS) at the Yopougon University Hospital in Abidjan. International Journal of Medical Sciences, 15 (3) (2013) 149-151.
[12] Amadou T.S, Boubakar B, Mamadou A.B, Place of the myelogram in the diagnosis of anemia in the hemato-oncology department of the Donka national hospital. Research en. 1 (630) (2014) 1-5. doi //dx.doi.org/10.13070/rs.fr.1.630
[13] Rodriguez-Abreu D, Bordoni A, Zucca E, Epidemiology of haematological malignancy. Annals of Oncology. 18(1) (2007): 3–8. doi: 10.1093/announce/mdl443.
[14] Le Guyader-Peyrou S, Defossez G, Dantony E, Mounier M, Cornet E, Uhry Z et al., National estimates of cancer incidence and mortality in metropolitan France between 1990 and 2018. Malignant haemopathies. Study from cancer registers of the Francim network. Saint-Maurice (Fra): Public Health France, (1) (2019) 372.
[15] Bruno V. The internal book 3rd edition, Hématologies. Medicine-Sciences Flammarion, France, (2007).
[16] Malam-Abdou B, Brah S, Djibrilla A, Andia A, Chefou M, Mahaman Sani SA, Beydou S, Daou M, Adehossi EO Chronic lymphocytic leukemia in Niger: a study of 99 cases in the Onco-Hematology department of the National Hospital of Niamey. Health Science Disease, 19(2) (2018) 93-96.
[17] Ngouadjeu DTE, Tomowiak C, Okalla C, Sume GE, Cazenave M, Araujo C, Banaos A, Mbatchou H, Luma H, Bauduer H, Epidemiological profile of hemopathies at the general hospital of Douala, Cameroon, from September 2007 to September 2011 Hemato Horizons, 03(02) (2013) 80-85.
[18] International Agency for Research on Cancer (IARC). Cancers attributable to lifestyle and the environment in metropolitan France. Lyons, (2018) 271.
[19] Monnereau A, Remontet L, Maynadié M, Binder‑Foucard F, Belot A, Troussard X et al., National estimate of cancer incidence in France between 1980 and 2012. Study based on network cancer registers Francim. Part 2 – Hematological malignancies. Saint‑Maurice: Health Watch Institute, (2013) 88.
[20] Le Guyader-Peyrou S, Defossez G, Dantony E, Mounier M, Cornet E, Uhry Z, et al., National estimates of cancer incidence and mortality in metropolitan France between 1990 and 2018. Hematological malignancies . Saint‑Maurice (Fra): Public Health France, (2019) 169.
[21] Schinasi L, Leon M.E, Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. International Journal Environment Res Public Health. 11(4) (2014) 4449-44527.
[22] Lasfargues G. Non-Hodgkin lymphomas and pesticides. Academic Bulletin Natle Medicine, nos7-8-9 (2017) 1161-1173.
[23] Jehannin‑Ligier K, Dantony E, Bossard N, Molinié F, Defossez G, Daubisse‑Marliac L, et al., Projection of cancer incidence and
mortality in metropolitan France in 2017. Technical report. Saint‑Maurice: Public Health France, (2017) 80.
[24] Morton L.M., Dissecting lymphoma incidence to inform epidemiologic and clinical research. Leuk Lymphoma, 54(8) (2013)1575-1576.
[25] Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al., SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, M.D. (2018)
[26] Amani Ahmed., The Outcomes of Sixty-Two Patients with Burkitt Lymphoma a Single-Center Study at King Abdulaziz Medical City Jeddah, Saudi Arabia. International Journal of Medical Science, 8(3) (2021) 1-5.